Clinical and research-related project areas

Our aim is to understand the implication of inter- and intra-tumoral heterogeneity on success and failure of CAR therapy to improve and adapt genetic engineering and manufacturing of novel immunotherapeutic products. Thus, providing patients promising and pioneering treatment options.